Luye Pharma Group (HK:2186) has released an update.
Luye Pharma Group Ltd. has announced that their new Parkinson’s disease treatment, Jinyouping (rotigotine microspheres for injection), has been approved for marketing in China, offering a once-a-week dosing schedule that promises improved patient compliance and a sustained therapeutic effect. This first-of-its-kind extended-release formulation aligns with continuous dopaminergic stimulation principles, aiming to better manage symptoms and enhance the quality of life for patients. The approval, supported by robust clinical trials, positions Jinyouping as a significant addition to Luye Pharma’s central nervous system therapeutic portfolio and addresses substantial unmet needs in Parkinson’s disease treatments.
For further insights into HK:2186 stock, check out TipRanks’ Stock Analysis page.
